LCTX

Lineage Cell Therapeutics, Inc. (LCTX) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic ("off-the-shelf") cell therapies. The company's primary focus includes the OpRegen program (in collaboration with Roche/Genentech) for geographic atrophy secondary to age-related macular degeneration, and the OPC1 program for spinal cord injury. All manufacturing operations are conducted at a facility in Jerusalem, Israel, which faces risks related to the ongoing Israel-Hamas war.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 56% year-over-year in Q2 and 49% year-over-year for the six months ended June 30, 2024. This was primarily driven by a decrease in collaboration revenues recognized under the Roche Agreement due to an increase in total estimated costs to be incurred.
• Expense Reduction: Research and development (R&D) expenses decreased 26% in Q2 and 27% year-over-year for the six-month period, largely due to cost reductions in the OPC1 and preclinical programs. General and administrative (G&A) expenses increased slightly (3% in Q2, 4% YTD) due to higher stock-based compensation and personnel costs.
• Capital Raise: In February 2024, the company raised approximately $13.8 million in net proceeds via a registered direct offering. Additionally, $70,000 was raised through the At-The-Market (ATM) program in the first half of 2024.
• Foreign Currency Impact: The company recorded a foreign currency transaction loss of $0.38 million in Q2 and $0.73 million YTD 2024, primarily related to the remeasurement of intercompany notes between the U.S. parent and Israeli subsidiary.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash, cash equivalents, and marketable securities ($38.5 million) are sufficient to fund planned operations for at least the next 12 months. The company expects to continue incurring significant operating losses.
• Operational Updates:
  • OpRegen: Enrollment in the Phase 2a clinical trial is complete. A new service agreement with Genentech was signed in May 2024 to support the program.
  • OPC1: The FDA review of the IND amendment for the proposed DOSED clinical study is ongoing. The company intends to open the first study site as soon as feasible following FDA confirmation.
• Key Risks:
  • Geopolitical Conflict: All manufacturing is located in Jerusalem, Israel. The ongoing Israel-Hamas war poses risks to operations, employee availability (military reserve call-ups), and facility safety.
  • Capital Requirements: The company will need significant additional capital to fund future operations and clinical trials. Failure to raise capital could force delays or cancellations of trials.
  • Legal Proceedings: A shareholder derivative action regarding the fairness of an intercompany agreement is pending in Israel, with a third-party valuation firm retained to assess the matter.

Investor Verification Checklist

• Verify the status of the FDA review for the OPC1 DOSED study IND amendment and the timeline for opening the first clinical site.
• Monitor the impact of the Israel-Hamas war on the Jerusalem manufacturing facility and employee availability.
• Review the remaining capacity under the At-The-Market (ATM) offering program ($39.97 million available) and the company's ability to access capital markets.
• Assess the potential financial impact of the pending shareholder derivative action in Israel regarding the intercompany agreement.
• Track the recognition of revenue under the Roche Agreement, which is sensitive to changes in estimated total collaboration costs.